Company intelligence / Profile preview

Biogenexis

Ownership: Private
Development stage: Other

Overview

Biogenexis is an emerging biotechnology company focused on developing next-generation therapies for metabolic disorders, including obesity and type 2 diabetes. The company leverages its expertise in incretin biology to design potent and selective agonists targeting the GLP-1 and GIP receptors. Biogenexis aims to improve patient outcomes by creating treatments with enhanced efficacy and better tolerability profiles compared to existing standards of care. Currently, the company's programs are in the pre-clinical stage of development.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Biogenexis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biogenexis.

Explore the full profile